Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBITDA Margin (2022 - 2025)

Atara Biotherapeutics' EBITDA Margin history spans 4 years, with the latest figure at 213.61% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 17481.0% year-over-year to 213.61%; the TTM value through Dec 2025 reached 27.06%, up 9313.0%, while the annual FY2025 figure was 27.06%, 9313.0% up from the prior year.
  • EBITDA Margin reached 213.61% in Q4 2025 per ATRA's latest filing, down from 124.56% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 38.72% in Q1 2025 to a low of 33339.37% in Q4 2022.
  • Average EBITDA Margin over 4 years is 3684.99%, with a median of 169.08% recorded in 2025.
  • The largest YoY upside for EBITDA Margin was 3190506bps in 2023 against a maximum downside of -896302bps in 2023.
  • A 4-year view of EBITDA Margin shows it stood at 33339.37% in 2022, then skyrocketed by 96bps to 1434.3% in 2023, then soared by 97bps to 38.8% in 2024, then crashed by -451bps to 213.61% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's EBITDA Margin are 213.61% (Q4 2025), 124.56% (Q3 2025), and 13.58% (Q2 2025).